Technical Analysis for BGNE - BeiGene, Ltd.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bullish Signal Line Cross | Bullish | 0.00% | |
Multiple of Ten Bullish | Other | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Gapped Up | Strength | 0.00% | |
Narrow Range Bar | Range Contraction | 4.29% | |
NR7 | Range Contraction | 4.29% | |
Inside Day | Range Contraction | 4.29% | |
Wide Bands | Range Expansion | 4.29% | |
Multiple of Ten Bullish | Other | 4.75% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
10 DMA Support | 2 days ago |
Outside Day | 2 days ago |
Fell Below Previous Day's Low | 2 days ago |
Down 1% | 2 days ago |
Reversed from Up | 2 days ago |
Get a Trading Sidekick!
- Earnings date: 09/27/2019
BeiGene, Ltd. Description
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Monoclonal Antibody Lymphoma Monoclonal Antibodies Oncogenes Protein Kinase Kras Bruton's Tyrosine Kinase Ras Subfamily Recombination Rp1
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 426.56 |
52 Week Low | 120.0 |
Average Volume | 342,252 |
200-Day Moving Average | 267.11 |
50-Day Moving Average | 170.46 |
20-Day Moving Average | 146.13 |
10-Day Moving Average | 133.12 |
Average True Range | 12.32 |
RSI | 41.86 |
ADX | 28.62 |
+DI | 18.65 |
-DI | 31.44 |
Chandelier Exit (Long, 3 ATRs) | 141.21 |
Chandelier Exit (Short, 3 ATRs) | 156.95 |
Upper Bollinger Bands | 174.43 |
Lower Bollinger Band | 117.83 |
Percent B (%b) | 0.34 |
BandWidth | 38.73 |
MACD Line | -12.33 |
MACD Signal Line | -12.70 |
MACD Histogram | 0.3718 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 152.54 | ||||
Resistance 3 (R3) | 151.56 | 145.50 | 150.00 | ||
Resistance 2 (R2) | 145.50 | 141.63 | 146.00 | 149.16 | |
Resistance 1 (R1) | 141.41 | 139.23 | 138.39 | 142.39 | 148.31 |
Pivot Point | 135.36 | 135.36 | 133.84 | 135.85 | 135.36 |
Support 1 (S1) | 131.27 | 131.48 | 128.24 | 132.25 | 126.33 |
Support 2 (S2) | 125.21 | 129.09 | 125.70 | 125.48 | |
Support 3 (S3) | 121.12 | 125.21 | 124.64 | ||
Support 4 (S4) | 122.10 |